[ADXS] Advaxis, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.62 Change: 0.41 (5.69%)
Ext. hours: Change: 0 (0%)

chart ADXS

Refresh chart

Strongest Trends Summary For ADXS

ADXS is in the long-term up 2421% in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. The company?s Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. The company has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. Its products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.97 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.44
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-57.87% ROE-63.14% ROI
Current Ratio12.18 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities38.41 M Cash From Investing Activities-340 K Cash From Operating Activities-9.73 M Gross Profit
Net Profit-13.86 M Operating Profit-13.84 M Total Assets51.69 M Total Current Assets48.57 M
Total Current Liabilities3.99 M Total Debt30 K Total Liabilities4.32 M Total Revenue
Technical Data
High 52 week7.61 Low 52 week0.43 Last close3.31 Last change0.3%
RSI18.9 Average true range0.71 Beta0.51 Volume687.29 K
Simple moving average 20 days-31.82% Simple moving average 50 days-39.52% Simple moving average 200 days10.96%
Performance Data
Performance Week-11.26% Performance Month-54.27% Performance Quart-36.95% Performance Half361.78%
Performance Year91.33% Performance Year-to-date16.14% Volatility daily9.22% Volatility weekly20.63%
Volatility monthly42.27% Volatility yearly146.44% Relative Volume327.71% Average Volume1.58 M
New High New Low


2020-05-14 08:00:10 | Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

2020-03-13 09:00:10 | Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

2020-03-03 16:01:10 | Advaxis to Present at the 2020 LD Micro Virtual Conference

2020-02-27 09:00:10 | Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

2020-02-20 08:00:10 | Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

2020-02-16 15:03:32 | The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions

2020-02-13 08:00:10 | Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

2020-02-11 08:00:10 | Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

2020-01-30 09:23:53 | Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings

2020-01-21 08:30:10 | Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

2020-01-07 08:00:10 | Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer

2019-12-22 17:08:44 | Is Advaxis, Inc. ADXS A Good Stock To Buy?

2019-12-20 08:00:00 | Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update

2019-12-20 05:04:46 | Did Changing Sentiment Drive Advaxis's NASDAQ:ADXS Share Price Down A Disastrous 99%?

2019-12-04 08:00:00 | Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference

2019-12-03 08:00:00 | Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer

2019-10-24 09:00:00 | Advaxis Announces Business and Pipeline Update

2019-10-10 08:00:00 | Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

2019-10-07 08:00:00 | Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

2019-09-19 06:36:15 | Is This A Catalyst To Buy Advaxis, Inc. NASDAQ:ADXS?

2019-09-10 07:36:12 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

2019-09-09 08:00:00 | Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

2019-08-22 08:00:00 | Advaxis, Inc. Issues Letter to Shareholders

2019-08-12 06:30:00 | BriaCell Appoints Richard J. Berman to Board of Directors

2019-07-25 11:30:00 | Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option

2019-07-24 07:08:12 | The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

2019-07-23 08:30:00 | Advaxis, Inc. Announces Pricing of $16 Million Public Offering

2019-07-15 08:00:00 | New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

2019-06-27 06:50:00 | Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study

2019-06-20 04:25:20 | Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT

2019-06-11 09:00:00 | Advaxis, Inc. to Host Earnings Call

2019-06-10 16:05:00 | Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

2019-06-04 08:00:00 | Advaxis to Host Business Update Conference Call on June 11, 2019

2019-05-25 09:48:01 | What Kind Of Investor Owns Most Of Advaxis, Inc. NASDAQ:ADXS?

2019-05-15 10:25:35 | Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

2019-05-15 08:00:00 | FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

2019-05-14 09:00:00 | Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

2019-05-13 15:00:00 | Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

2019-05-07 09:00:00 | Advaxis to Participate in Five Upcoming Industry Conferences

2019-04-18 17:45:09 | Advaxis ADXS Stock Sinks As Market Gains: What You Should Know

2019-04-16 10:54:02 | QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

2019-04-10 08:43:12 | Twist Bioscience TWST Looks Good: Stock Adds 6.5% in Session

2019-04-08 09:30:01 | Is Advaxis ADXS Outperforming Other Medical Stocks This Year?

2019-04-03 16:31:00 | Why Range Resources, Advaxis, and StoneCo Slumped Today

2019-04-03 08:19:01 | The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

2019-04-03 07:44:00 | Advaxis' stock plummets after public offering prices at deep discount

2019-04-03 07:30:00 | Advaxis Announces Pricing of Its Public Offering of Common Stock

2019-04-02 16:05:00 | Advaxis, Inc. Announces Proposed Public Offering of Common Stock

2019-04-02 09:44:01 | Advaxis Up on Positive Early-Stage Immunotherapy Study Data

2019-04-01 16:31:00 | Why Wynn Resorts, Advaxis, and Roku Jumped Today